Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Archives of Biochemistry and Biophysics

• Publication date

  2004-04-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.ABB.2004.02.009PMID 15047184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells

  2004cited by this paper
• Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.

  2003cited by this paper
• Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)

  2003cited by this paper
• Comparison of Prostaglandin F2α, Bimatoprost (Prostamide), and Butaprost (EP2 Agonist) on Cyr61 and Connective Tissue Growth Factor Gene Expression*

  2003cited by this paper
• Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.

  2003cited by this paper
• Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.

  2003cited by this paper
• Hydrolysis of Bimatoprost (Lumigan) to its Free Acid by Ocular Tissue In Vitro

  2003cited by this paper
• Endocannabinoids in the new millennium.

  2002cited by this paper
• Metabolism of the Endocannabinoids, 2-Arachidonylglycerol and Anandamide, into Prostaglandin, Thromboxane, and Prostacyclin Glycerol Esters and Ethanolamides*

  2002cited by this paper
• Endocannabinoids in the new millennium.

  2002cited by this paper
• Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide.

  2002cited by this paper
• Metabolism of Prostaglandin Glycerol Esters and Prostaglandin Ethanolamides in Vitro and in Vivo *

  2001cited by this paper
• The pharmacology of bimatoprost (Lumigan).

  2001cited by this paper
• Oxidoreductases in Lipoxin A4 Metabolic Inactivation

  2000cited by this paper
• Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor

  2000cited by this paper
• Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds

  2000cited by this paper
• Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2*

  2000cited by this paper
• cDNA cloning, expression and characterization of human prostaglandin F synthase.

  1999cited by this paper
• Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide

  1999cited by this paper
• cDNA cloning, expression and characterization of human prostaglandin F synthase 1

  1999cited by this paper
• cDNA Cloning, Expression, and Mutagenesis Study of Liver-type Prostaglandin F Synthase*

  1999cited by this paper
• Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2*

  1997cited by this paper
• Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.

  1993cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper
• Purification and characterization of prostaglandin F synthase from bovine liver.

  1992cited by this paper
• Expression of bovine lung prostaglandin F synthase in Escherichia coli.

  1991cited by this paper
• Structural similarity of bovine lung prostaglandin F synthase to lens epsilon-crystallin of the European common frog.

  1988cited by this paper
• Stereospecific conversion of prostaglandin D2 to (5Z,13E)-(15S)-9 alpha-11 beta,15-trihydroxyprosta-5,13-dien-1-oic acid (9 alpha,11 beta-prostaglandin F2) and of prostaglandin H2 to prostaglandin F2 alpha by bovine lung prostaglandin F synthase.

  1986cited by this paper
• Enzymatic formation of prostaglandin F2 alpha from prostaglandin H2 and D2. Purification and properties of prostaglandin F synthetase from bovine lung.

  1985cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Screening, characterization, and determination of suspected additives bimatoprost and latanoprost in cosmetics using NMR and LC–MS methods

  2023cites this paper
• Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.

  2022cites this paper
• Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol andN-acyl-ethanolamine families.

  2022cites this paper
• Ablation of Selenbp1 Alters Lipid Metabolism via the Pparα Pathway in Mouse Kidney

  2021cites this paper
• Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure.

  2021cites this paper
• Interplay Between Oxidative Stress, Cyclooxygenases, and Prostanoids in Cardiovascular Diseases

  2020cites this paper
• Gene deletion studies reveal a critical role for prostamide/prostaglandin F2α synthase in prostamide F2α formation

  2020cites this paper
• The role of n-3 PUFA-derived fatty acid derivatives and their oxygenated metabolites in the modulation of inflammation.

  2019cites this paper
• The characterization of 17β-hydroxysteroid dehydrogenase type 2 (17βHSD2) activity towards novel C19 substrates.

  2017cites this paper
• Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival

  2017cites this paper
• Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation

  2017cites this paper
• The roles of prostaglandin E2, prostaglandin F2α and aldo-keto reductase 1C isoenzymes in endometriosis and breast cancer

  2017cites this paper
• In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.

  2016cites this paper
• Protective Action of Anandamide and Its COX-2 Metabolite against l-Homocysteine-Induced NLRP3 Inflammasome Activation and Injury in Podocytes

  2016cites this paper
• Prostamide F2α Biosynthesizing Enzymes

  2015cites this paper
• Oxidative Metabolites of Endocannabinoids Formed by Cyclooxygenase-2

  2015cites this paper
• Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases.

  2015cites this paper
• Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea[S]

  2015cites this paper
• Regulation of inflammation by cannabinoids, the endocannabinoids 2‐arachidonoyl‐glycerol and arachidonoyl‐ethanolamide, and their metabolites

  2015cites this paper
• Chapter 6 – The Pharmacology of Prostaglandin F2α Ethanolamide and Bimatoprost Reveals a Unique Feedback Mechanism on Endocannabinoid Actions

  2015cites this paper
• Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.

  2014cites this paper
• Determination of prostaglandin analogs in cosmetic products by high performance liquid chromatography with tandem mass spectrometry.

  2014cites this paper
• COX-2-derived endocannabinoid metabolites as novel inflammatory mediators.

  2014cites this paper
• Prostamide F2α receptor antagonism combined with inhibition of FAAH may block the pro‐inflammatory mediators formed following selective FAAH inhibition

  2014influential citation
• Recent Progress in Prostaglandin F2α Ethanolamide (Prostamide F2α) Research and Therapeutics

  2013influential citation
• Anandamide-derived Prostamide F2α Negatively Regulates Adipogenesis

  2013cites this paper
• Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3

  2012cites this paper
• Prostaglandins vis-à-vis bovine embryonic mortality: a review

  2012cites this paper
• Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

  2011cites this paper
• Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.

  2011cites this paper
• Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways

  2011cites this paper
• The Use of Prostaglandin Analogs in the Uveitic Patient

  2011cites this paper
• Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

  2011cites this paper
• Bimatoprost Effects on Aqueous Humor Dynamics in Monkeys

  2010cites this paper
• Steroid Hormone Transforming Aldo‐Keto Reductases and Cancer

  2009cites this paper
• CHAPTER 23 – Prostaglandins

  2009cites this paper
• Prostanoid receptor antagonists: development strategies and therapeutic applications

  2009cites this paper
• Bimatoprost – a review

  2009cites this paper
• Molecular Characterization of a Novel Type of Prostamide/Prostaglandin F Synthase, Belonging to the Thioredoxin-like Superfamily*

  2008cites this paper
• Endocannabinoids: synthesis and degradation.

  2008cites this paper
• Two pathways for prostaglandin F2 alpha synthesis by the primate periovulatory follicle.

  2008influential citation
• Prostamides (prostaglandin‐ethanolamides) and their pharmacology

  2008influential citation
• Human liver dihydrodiol dehydrogenase 1-catalyzed reaction generating 9alpha,11beta-prostaglandin F2 from prostaglandin D2 followed by micellar electrokinetic chromatography.

  2008cites this paper
• An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.

  2008cites this paper
• An improved LC-MS/MS method for the quantification of prostaglandins E(2) and D(2) production in biological fluids.

  2008cites this paper
• Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes

  2008cites this paper
• The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products.

  2008influential citation
• Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin‐ethanolamides) in the feline iris

  2007cites this paper
• A historical perspective and recent advances in prostamide research and therapeutics.

  2007cites this paper
• Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms.

  2007cites this paper
• Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost.

  2006cites this paper
• Bimatoprost for glaucoma therapy: pharmacology, clinical efficacy and controversy

  2006cites this paper
• Simultaneous analysis of prostanoids using liquid chromatography/high-field asymmetric waveform ion mobility spectrometry/tandem mass spectrometry.

  2006cites this paper
• Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2.

  2005cites this paper
• Simultaneous analysis of prostaglandin glyceryl esters and prostaglandins by electrospray tandem mass spectrometry.

  2005cites this paper
• Current literature in mass spectrometry.

  2004cites this paper